223 related articles for article (PubMed ID: 37211066)
21. The Future of Immunotherapy in the Treatment of Small Cell Lung Cancer.
Horn L; Reck M; Spigel DR
Oncologist; 2016 Aug; 21(8):910-21. PubMed ID: 27354668
[TBL] [Abstract][Full Text] [Related]
22. Update 2021: Management of Small Cell Lung Cancer.
Tariq S; Kim SY; Monteiro de Oliveira Novaes J; Cheng H
Lung; 2021 Dec; 199(6):579-587. PubMed ID: 34757446
[TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness analysis of pembrolizumab plus chemotherapy as first-line therapy for extensive-stage small-cell lung cancer.
Liu Q; Tan C; Yi L; Wan X; Peng L; Li J; Luo X; Zeng X
PLoS One; 2021; 16(11):e0258605. PubMed ID: 34780478
[TBL] [Abstract][Full Text] [Related]
24. [Efficacy of chemotherapy combined hyperfractionated accelerated radiotherapy on limited small cell lung cancer].
Hu X; Bao Y; Chen YY; Gao JM; Wang WH; Liu Y; He H; Sun ZW; Poudel S; Wang Y; Zhuang TT; Zhang L; Chen M
Ai Zheng; 2008 Oct; 27(10):1088-93. PubMed ID: 18851790
[TBL] [Abstract][Full Text] [Related]
25. Management of small-cell lung cancer: incremental changes but hope for the future.
Hann CL; Rudin CM
Oncology (Williston Park); 2008 Nov; 22(13):1486-92. PubMed ID: 19133604
[TBL] [Abstract][Full Text] [Related]
26. Combination Treatment of the Oral CHK1 Inhibitor, SRA737, and Low-Dose Gemcitabine Enhances the Effect of Programmed Death Ligand 1 Blockade by Modulating the Immune Microenvironment in SCLC.
Sen T; Della Corte CM; Milutinovic S; Cardnell RJ; Diao L; Ramkumar K; Gay CM; Stewart CA; Fan Y; Shen L; Hansen RJ; Strouse B; Hedrick MP; Hassig CA; Heymach JV; Wang J; Byers LA
J Thorac Oncol; 2019 Dec; 14(12):2152-2163. PubMed ID: 31470128
[TBL] [Abstract][Full Text] [Related]
27. IMpower, CASPIAN, and more: exploring the optimal first-line immunotherapy for extensive-stage small cell lung cancer.
Huang C; Gan GN; Zhang J
J Hematol Oncol; 2020 Jun; 13(1):69. PubMed ID: 32503595
[TBL] [Abstract][Full Text] [Related]
28. Emerging drugs for small-cell lung cancer.
Metro G; Cappuzzo F
Expert Opin Emerg Drugs; 2009 Dec; 14(4):591-606. PubMed ID: 19694501
[TBL] [Abstract][Full Text] [Related]
29. The landscape of immune checkpoint inhibitor therapy in advanced lung cancer.
Wang C; Li J; Zhang Q; Wu J; Xiao Y; Song L; Gong H; Li Y
BMC Cancer; 2021 Aug; 21(1):968. PubMed ID: 34454455
[TBL] [Abstract][Full Text] [Related]
30. Immune Checkpoint Inhibitors and Chemoradiation for Limited-Stage Small Cell Lung Cancer.
Schlick B; Shields MD; Marin-Acevedo JA; Patel I; Pellini B
Curr Treat Options Oncol; 2022 Aug; 23(8):1104-1120. PubMed ID: 35716328
[TBL] [Abstract][Full Text] [Related]
31. A potential treatment option for transformed small-cell lung cancer on PD-L1 inhibitor-based combination therapy improved survival.
Zhang CY; Sun H; Su JW; Chen YQ; Zhang SL; Zheng MY; Li YF; Huang J; Zhang C; Tai ZX; Cai M; Zhang XC; Su J; Xu CR; Yan HH; Chen HJ; Wu YL; Yang JJ
Lung Cancer; 2023 Jan; 175():68-78. PubMed ID: 36473332
[TBL] [Abstract][Full Text] [Related]
32. The role of thoracic consolidative radiotherapy in the setting of immunotherapy in extensive stage small cell lung cancer.
Verma S; Young S; Louie AV; Palma D; Breadner D
Ther Adv Med Oncol; 2023; 15():17588359231192399. PubMed ID: 37655208
[TBL] [Abstract][Full Text] [Related]
33. [Effects of Local Radiation Combined with Chemotherapy in the treatment of
Patients with Extensive-stage Small Cell Lung Cancer].
Wu D; Fang J; Nie J; Dai L; Chen X; Zhang J; Hu W; Han J; Ma X; Tian G; Han S; Long J; Wang Y
Zhongguo Fei Ai Za Zhi; 2015 May; 18(5):272-9. PubMed ID: 25975297
[TBL] [Abstract][Full Text] [Related]
34. Small cell lung cancer: a slightly less orphan disease after immunotherapy.
Remon J; Aldea M; Besse B; Planchard D; Reck M; Giaccone G; Soria JC
Ann Oncol; 2021 Jun; 32(6):698-709. PubMed ID: 33737119
[TBL] [Abstract][Full Text] [Related]
35. A brief report on combination chemotherapy and anti-programmed death (ligand) 1 treatment in small-cell lung cancer: Did we choose the optimal chemotherapy backbone?
Mankor JM; Zwierenga F; Dumoulin DW; Neefjes JJC; Aerts JGJV
Eur J Cancer; 2020 Sep; 137():40-44. PubMed ID: 32739768
[TBL] [Abstract][Full Text] [Related]
36. [Clinical Trial Progress and Application of Immune Checkpoint Inhibitors
in the Treatment of Small Cell Lung Cancer].
Zhang H; Li X; Li X; Su Y
Zhongguo Fei Ai Za Zhi; 2021 Nov; 24(11):790-795. PubMed ID: 34802211
[TBL] [Abstract][Full Text] [Related]
37. Combining radiation therapy with immune checkpoint blockade for the treatment of small cell lung cancer.
Saxena A
Semin Cancer Biol; 2023 May; 90():45-56. PubMed ID: 36787870
[TBL] [Abstract][Full Text] [Related]
38. Anti-PD-L1 immune checkpoint inhibitors in combination with etoposide and platinum for extensive-stage small cell lung cancer: a case report.
Xue L; Chen B; Lin J; Peng J
Ann Palliat Med; 2021 Jan; 10(1):828-835. PubMed ID: 33545805
[TBL] [Abstract][Full Text] [Related]
39. Immunotherapeutic maintenance treatment with toll-like receptor 9 agonist lefitolimod in patients with extensive-stage small-cell lung cancer: results from the exploratory, controlled, randomized, international phase II IMPULSE study.
Thomas M; Ponce-Aix S; Navarro A; Riera-Knorrenschild J; Schmidt M; Wiegert E; Kapp K; Wittig B; Mauri C; Dómine Gómez M; Kollmeier J; Sadjadian P; Fröhling KP; Huber RM; Wolf M;
Ann Oncol; 2018 Oct; 29(10):2076-2084. PubMed ID: 30137193
[TBL] [Abstract][Full Text] [Related]
40. PARP inhibitor plus radiotherapy reshapes an inflamed tumor microenvironment that sensitizes small cell lung cancer to the anti-PD-1 immunotherapy.
Zhang N; Gao Y; Huang Z; Dai P; Luo Y; Wu Q; Jiang X; Sun W; Zhang J; Han L; Zhang J; Gong Y; Xie C
Cancer Lett; 2022 Oct; 545():215852. PubMed ID: 35926817
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
